Beclomethasone/Formoterol in Extra-Fine Formulation Improves Small Airway Dysfunction in COPD Patients

Area of Science:

• Pulmonology
• Respiratory Medicine
• Pharmacology

Background:

• Small airway dysfunction (SAD) is a key element in chronic obstructive pulmonary disease (COPD).
• Targeting SAD offers a potential therapeutic strategy for COPD management.
• The efficacy of extra-fine formulations in addressing SAD requires further investigation.

Purpose of the Study:

• To evaluate the effect of an extra-fine beclomethasone dipropionate/formoterol fumarate (BDP/FF) NEXThaler® formulation on SAD in COPD patients.
• To assess the impact of this treatment on patients' quality of life.
• To explore the potential of SAD as a specific pharmacological target in COPD.

Main Methods:

• A study involving 43 COPD patients with severe airflow obstruction and recent exacerbations.
• Treatment with BDP/FF NEXThaler® 100/6 μg b.i.d. for 12 weeks with assessments at baseline, 6, and 12 weeks.
• Evaluation of small airway resistance (R5-R20) and lung volumes (RV/TLC) using impulse oscillometry, spirometry, and plethysmography, alongside COPD Assessment Test (CAT) and mMRC scores.

Main Results:

• Significant improvement in R5-R20, indicating reduced small airway resistance, was observed from baseline to weeks 6 and 12 (p < 0.05).
• COPD Assessment Test (CAT) scores significantly improved, reflecting a better quality of life (p < 0.05).
• A correlation was found between improvements in CAT scores and changes in R5-R20 and RV/TLC.

Conclusions:

• Treatment with the extra-fine BDP/FF formulation effectively improved functional parameters related to small airway disease in COPD patients.
• The study demonstrates a positive impact on the health status and quality of life for COPD patients.
• This formulation represents a promising therapeutic option for addressing small airway dysfunction in COPD.